Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

4-Methylpyrazole protects against acetaminophen hepatotoxicity in mice and in primary human hepatocytes.

Akakpo JY, Ramachandran A, Kandel SE, Ni HM, Kumer SC, Rumack BH, Jaeschke H.

Hum Exp Toxicol. 2018 Dec;37(12):1310-1322. doi: 10.1177/0960327118774902. Epub 2018 May 9.

PMID:
29739258
2.

Abundance of Phase 1 and 2 Drug-Metabolizing Enzymes in Alcoholic and Hepatitis C Cirrhotic Livers: A Quantitative Targeted Proteomics Study.

Prasad B, Bhatt DK, Johnson K, Chapa R, Chu X, Salphati L, Xiao G, Lee C, Hop CECA, Mathias A, Lai Y, Liao M, Humphreys WG, Kumer SC, Unadkat JD.

Drug Metab Dispos. 2018 Jul;46(7):943-952. doi: 10.1124/dmd.118.080523. Epub 2018 Apr 25.

3.

Interpreting Outcomes in DCDD Liver Transplantation: First Report of the Multicenter IDOL Consortium.

Goldberg DS, Karp SJ, McCauley ME, Markmann JF, Croome KP, Taner CB, Heimbach JK, Leise MD, Fryer JP, Bohorquez HE, Cohen AJ, Gilroy RK, Kumer SC, Foley DP, Karim AS, Hernandez-Alejandro R, Levstik MA, Abt PL.

Transplantation. 2017 May;101(5):1067-1073. doi: 10.1097/TP.0000000000001656.

PMID:
28114173
4.

Microcystin-LR induced liver injury in mice and in primary human hepatocytes is caused by oncotic necrosis.

Woolbright BL, Williams CD, Ni H, Kumer SC, Schmitt T, Kane B, Jaeschke H.

Toxicon. 2017 Jan;125:99-109. doi: 10.1016/j.toxicon.2016.11.254. Epub 2016 Nov 23.

5.

Transporter Expression in Liver Tissue from Subjects with Alcoholic or Hepatitis C Cirrhosis Quantified by Targeted Quantitative Proteomics.

Wang L, Collins C, Kelly EJ, Chu X, Ray AS, Salphati L, Xiao G, Lee C, Lai Y, Liao M, Mathias A, Evers R, Humphreys W, Hop CE, Kumer SC, Unadkat JD.

Drug Metab Dispos. 2016 Nov;44(11):1752-1758. Epub 2016 Aug 19.

6.

Increased hepatic receptor interacting protein kinase 3 expression due to impaired proteasomal functions contributes to alcohol-induced steatosis and liver injury.

Wang S, Ni HM, Dorko K, Kumer SC, Schmitt TM, Nawabi A, Komatsu M, Huang H, Ding WX.

Oncotarget. 2016 Apr 5;7(14):17681-98. doi: 10.18632/oncotarget.6893.

7.

Lack of Direct Cytotoxicity of Extracellular ATP against Hepatocytes: Role in the Mechanism of Acetaminophen Hepatotoxicity.

Xie Y, Woolbright BL, Kos M, McGill MR, Dorko K, Kumer SC, Schmitt TM, Jaeschke H.

J Clin Transl Res. 2015;1(2):100-106. Epub 2015 Sep 30.

8.

Mitochondrial protein adducts formation and mitochondrial dysfunction during N-acetyl-m-aminophenol (AMAP)-induced hepatotoxicity in primary human hepatocytes.

Xie Y, McGill MR, Du K, Dorko K, Kumer SC, Schmitt TM, Ding WX, Jaeschke H.

Toxicol Appl Pharmacol. 2015 Dec 1;289(2):213-22. doi: 10.1016/j.taap.2015.09.022. Epub 2015 Sep 30.

9.

Lack of direct cytotoxicity of extracellular ATP against hepatocytes: role in the mechanism of acetaminophen hepatotoxicity.

Xie Y, Woolbright BL, Kos M, McGill MR, Dorko K, Kumer SC, Schmitt TM, Jaeschke H.

J Clin Transl Res. 2015 Sep 30;1(2):1-7. eCollection 2015 Sep 30.

10.

Bile acid-induced necrosis in primary human hepatocytes and in patients with obstructive cholestasis.

Woolbright BL, Dorko K, Antoine DJ, Clarke JI, Gholami P, Li F, Kumer SC, Schmitt TM, Forster J, Fan F, Jenkins RE, Park BK, Hagenbuch B, Olyaee M, Jaeschke H.

Toxicol Appl Pharmacol. 2015 Mar 15;283(3):168-77. doi: 10.1016/j.taap.2015.01.015. Epub 2015 Jan 28.

11.

Late-onset renal vein thrombosis: A case report and review of the literature.

Hogan JL, Rosenthal SJ, Yarlagadda SG, Jones JA, Schmitt TM, Kumer SC, Kaplan B, Deas SL, Nawabi AM.

Int J Surg Case Rep. 2015;6C:73-6. doi: 10.1016/j.ijscr.2014.09.027. Epub 2014 Nov 21.

12.

Combined transmesenteric and transhepatic recanalization of chronic portal and mesenteric vein occlusion to treat bleeding duodenal varices.

Sabri SS, Caldwell SH, Kumer SC, Schmitt TM, Maluf DG, Angle JF, Saad WE.

J Vasc Interv Radiol. 2014 Aug;25(8):1295-9. doi: 10.1016/j.jvir.2013.11.021.

PMID:
25085062
13.

Mechanisms of acetaminophen-induced cell death in primary human hepatocytes.

Xie Y, McGill MR, Dorko K, Kumer SC, Schmitt TM, Forster J, Jaeschke H.

Toxicol Appl Pharmacol. 2014 Sep 15;279(3):266-74. doi: 10.1016/j.taap.2014.05.010. Epub 2014 Jun 3.

14.

Donor risk index predicts graft failure reliably but not post-transplant infections.

Rosenberger LH, Gillen JR, Hranjec T, Stokes JB, Brayman KL, Kumer SC, Schmitt TM, Sawyer RG.

Surg Infect (Larchmt). 2014 Apr;15(2):94-8. doi: 10.1089/sur.2013.035. Epub 2013 Nov 27.

15.

Self expandable metal stents for anastomotic stricture following liver transplant.

Cerecedo-Rodriguez J, Phillips M, Figueroa-Barojas P, Kumer SC, Gaidhane M, Schmitt T, Kahaleh M.

Dig Dis Sci. 2013 Sep;58(9):2661-6. doi: 10.1007/s10620-013-2703-0. Epub 2013 May 24.

PMID:
23703448
16.

Impact of stem cell marker expression on recurrence of TACE-treated hepatocellular carcinoma post liver transplantation.

Zeng Z, Ren J, O'Neil M, Zhao J, Bridges B, Cox J, Abdulkarim B, Schmitt TM, Kumer SC, Weinman SA.

BMC Cancer. 2012 Dec 7;12:584. doi: 10.1186/1471-2407-12-584.

17.

Quantifying increased hepatic arterial flow with test balloon occlusion of the splenic artery in liver transplant recipients with suspected splenic steal syndrome: quantitative digitally subtracted angiography correlation with arterial Doppler parameters.

Saad WE, Anderson CL, Kowarschik M, Turba UC, Schmitt TM, Kumer SC, Matsumoto AH, Angle JF.

Vasc Endovascular Surg. 2012 Jul;46(5):384-92. doi: 10.1177/1538574412449394. Epub 2012 Jun 6.

PMID:
22677799
18.

Elderly recipients of hepatitis C positive renal allografts can quickly develop liver disease.

Flohr TR, Bonatti H, Hranjec T, Keith DS, Lobo PI, Kumer SC, Schmitt TM, Sawyer RG, Pruett TL, Roberts JP, Brayman KL.

J Surg Res. 2012 Aug;176(2):629-38. doi: 10.1016/j.jss.2011.10.028. Epub 2011 Nov 19.

19.

Regional variability in symptom-based MELD exceptions: a response to organ shortage?

Argo CK, Stukenborg GJ, Schmitt TM, Kumer SC, Berg CL, Northup PG.

Am J Transplant. 2011 Nov;11(11):2353-61. doi: 10.1111/j.1600-6143.2011.03738.x.

20.

Evolution of β-Cell Replacement Therapy in Diabetes Mellitus: Islet Cell Transplantation.

Jahansouz C, Jahansouz C, Kumer SC, Brayman KL.

J Transplant. 2011;2011:247959. doi: 10.1155/2011/247959. Epub 2011 Oct 15.

21.

Endovascular therapy for hepatic artery stenosis and thrombosis following liver transplantation.

Sabri SS, Saad WE, Schmitt TM, Turba UC, Kumer SC, Park AW, Matsumoto AH, Angle JF.

Vasc Endovascular Surg. 2011 Jul;45(5):447-52. doi: 10.1177/1538574411407088. Epub 2011 May 13.

PMID:
21571780
22.

Evolution of β-Cell Replacement Therapy in Diabetes Mellitus: Pancreas Transplantation.

Jahansouz C, Kumer SC, Ellenbogen M, Brayman KL.

Diabetes Technol Ther. 2011 Mar;13(3):395-418. doi: 10.1089/dia.2010.0133. Epub 2011 Feb 7. Review.

PMID:
21299398
23.

Liver transplantation for T3 lesions has higher waiting list mortality but similar survival compared to T1 and T2 lesions.

Schmitt TM, Kumer SC, Shah N, Argo CK, Northup PG.

Ann Hepatol. 2010 Oct-Dec;9(4):390-6.

24.

Liver allografts from hepatitis C positive donors can offer good outcomes in hepatitis C positive recipients: a US National Transplant Registry analysis.

Northup PG, Argo CK, Nguyen DT, McBride MA, Kumer SC, Schmitt TM, Pruett TL.

Transpl Int. 2010 Oct;23(10):1038-44. doi: 10.1111/j.1432-2277.2010.01092.x.

25.

Electronic images of the month. Duodenal ulceration following variceal embolization with coils and vascular plugs.

Mahajan A, Kumer SC, Wang AY.

Clin Gastroenterol Hepatol. 2010 Jun;8(6):e63-4. doi: 10.1016/j.cgh.2009.12.019. Epub 2010 Jan 6. No abstract available.

PMID:
20060065
26.

Combined liver-kidney and liver transplantation in patients with renal failure outcomes in the MELD era.

Schmitt TM, Kumer SC, Al-Osaimi A, Shah N, Argo CK, Berg C, Pruett TL, Northup PG.

Transpl Int. 2009 Sep;22(9):876-83. doi: 10.1111/j.1432-2277.2009.00887.x. Epub 2009 Apr 27.

27.

Advanced recipient age (>60 years) alone should not be a contraindication to liver retransplantation.

Schmitt TM, Kumer SC, Pruett TL, Argo CK, Northup PG.

Transpl Int. 2009 Jun;22(6):601-5. doi: 10.1111/j.1432-2277.2009.00845.x. Epub 2009 Feb 10.

28.

A monoclonal antibody to tryptophan hydroxylase: applications and identification of the epitope.

Haycock JW, Kumer SC, Lewis DA, Vrana KE, Stockmeier CA.

J Neurosci Methods. 2002 Mar 15;114(2):205-12.

PMID:
11856572
29.

Patterns of conducted vasomotor response in the mouse.

Kumer SC, Damon DN, Duling BR.

Microvasc Res. 2000 Mar;59(2):310-5. No abstract available.

PMID:
10684737
30.

Carboxyl terminal deletion analysis of tryptophan hydroxylase.

Mockus SM, Kumer SC, Vrana KE.

Biochim Biophys Acta. 1997 Oct 17;1342(2):132-40.

PMID:
9392522
31.

Amino-terminal analysis of tryptophan hydroxylase: protein kinase phosphorylation occurs at serine-58.

Kumer SC, Mockus SM, Rucker PJ, Vrana KE.

J Neurochem. 1997 Oct;69(4):1738-45.

32.
33.

Tyrosinase mRNA is expressed in human substantia nigra.

Xu Y, Stokes AH, Freeman WM, Kumer SC, Vogt BA, Vrana KE.

Brain Res Mol Brain Res. 1997 Apr;45(1):159-62.

PMID:
9105685
34.

Intricate regulation of tyrosine hydroxylase activity and gene expression.

Kumer SC, Vrana KE.

J Neurochem. 1996 Aug;67(2):443-62. Review.

PMID:
8764568
35.

Recombinant rabbit tryptophan hydroxylase is a substrate for cAMP-dependent protein kinase.

Vrana KE, Rucker PJ, Kumer SC.

Life Sci. 1994;55(13):1045-52.

PMID:
8084209

Supplemental Content

Loading ...
Support Center